CombiMatrix Corp., of Irvine, Calif., appointed Richard Ding and Joseph Limber to its board...and Christine Mikail, executive vice president, corporate development, general counsel and secretary

ImmunoGen Inc., of Waltham, Mass., added Kristine Peterson and Dean Mitchell to its board...and added Eunan Maguire senior vice president of strategy and corporate development

ImmunoGen Inc., of Waltham, Mass., added Kristine Peterson and Dean Mitchell to its board...and added Eunan Maguire senior vice president of strategy and corporate development

Acella Pharmaceuticals Inc., of Atlanta, appointed Allen Fields vice president and head of R&D...Adeona Pharmaceuticals Inc., of Ann Arbor, Mich., appointed Jeff Riley president and CEO, added C. Evan Ballantyne as chief financial officer and named Scott L. Tarriff and Nelson K. Stacks to the board...AMAG Pharmaceuticals Inc., of Lexington, Mass., appointed Rajiv De Silva and Gino Santini to its board

The revisions will reflect technological advancements and marketing developments that have emerged over the past decade...Viewed as a way to take the hard choices of curbing Medicare expenses out of the hands of Congress, the board – made up of presidential appointments confirmed by the Senate – is charged with cutting Medicare costs if its spending exceeds a predetermined target growth rate. (See BioWorld Today, July 14, 2011, and Sept. 20, 2011.) Although President Barack Obama has proposed

Pharmalink AB, of Stockholm, Sweden, elected Anders Wiklung chairman and added Elisabeth Lindner to the board...Promosome LLC, of New York, added Edward R. Robinson and Loren A. Busby to its board...It also appointed Louis Brenner chief medical officer and elected Kurt Graves chairman

Emerald BioStructures Inc., of Bainbridge Island, Wash., appointed Johan Pontin chairman and CEO...Fate Therapeutics Inc., of San Diego, appointed William H. Rastetter chairman and interim CEO...Forma Therapeutics Inc., of Watertown, Mass., named Jaime Escobedo vice president of biology and Mark J. Tebbe vice president of medicinal and computational chemistry and appointed Dennis France executive director and head of biomolecular screening

Codexis Inc., of Redwood City, Calif., named Wesley J. Bolsen vice president and chief marketing officer...Curis Inc., of Lexington, Mass., appointed Maurizio Voi chief medical and chief development officer

Accera Inc., of Broomfield, Colo., appointed Holger Kunze CEO and board member...BioTime Inc., of Alameda, Calif., and its subsidiary, OncoCyte Corp., each appointed Andrew von Eschenbach to their boards...CBio Ltd., of Brisbane, Australia, named Ralph Craven chairman and appointed Helen Cameron interim managing director

Hilary Malone as vice president and chief regulatory and compliance officer...and Jim Rouse as vice president and chief information officer

It also named Gerald Commissiong president and CEO and appointed Owen Garrick strategic advisor to its board...Anaptys Bio Inc., of San Diego, named Carol G. Gallagher executive chair and promoted Hamza Suria to chief business officer and acting CEO

Savient Pharmaceuticals Inc., of East Brunswick, N.J., appointed Kenneth J. Zuerblis executive vice president and chief financial officer...Silence Therapeutics plc, of London, appointed Thomas Christely CEO and named Tony Sedgwick chief business officer...Sucampo Pharmaceuticals Inc., of Bethesda, Md., added Greg Deener as vice president of marketing, strategy and implementation

Affimed Therapeutics AG, of Heidelberg, Germany, named Adi Hoess CEO and appointed Rolf Guenther chief operating officer...and Alexander H. Burgess as vice president of marketing...CardioDx, of Palo Alto, Calif., named Andrew L. Guggenhime chief financial officer and appointed Mark Monane chief medical officer

Creabilis SA, of Luxembourg, named Alex Leech vice president and head of finance of operations, appointed James Sandy senior vice president and head of development and added Peter Spargo as senior vice president for chemistry, manufacturing and controls

Tim Henkel as executive vice president and head of R&D...Doug Gessl as chief operating officer and chief financial officer...and Lisa Wittmer as vice president of regulatory affairs

PharmacoFore Inc., of San Carlos, Calif., appointed Joseph Stauffer chief medical officer and vice president of corporate strategy and named Narinder Banait vice president of intellectual property...ProtAffin AG, of Graz, Austria, appointed Frank Walsh chairman and named Tim Edwards to the board

Ascletis Inc., of Research Triangle Park, N.C., and Hangzhou, China, appointed Allan Baxter chief strategy officer...Genesis Biopharma Inc., of Los Angeles, added David Voyticky and Merrill A. McPeak to its board and named Laszlo Radvanyi to its scientific and medical advisory board

The people who are assigned to the committee include Michael Conte, William Marston, Richard Powell and Michael Smith...Ablexis LLC, of San Francisco, appointed Jake Bauer senior director of corporate development and business operations...Agennix AG, of Planegg, Germany, appointed Jill Porter senior vice president of pharmaceutical development and appointed Christine Boisclair senior vice president of global regulatory affairs

Vivo Ventures LLC, of Palo Alto, Calif., promoted Chen Yu and James Zhao to managing partners...Xceleron Ltd., of York, UK, appointed David Roblin to its board and named Stuart Best senior director of operations...XOMA Ltd., of Berkeley, Calif., appointed Paul Rubin vice president and chief medical officer